专题：Histone Deacetylase Inhibitors Research

This cluster of papers explores the role of histone deacetylases (HDACs) in regulating cellular functions, gene expression, and epigenetic modifications. It covers the use of HDAC inhibitors in cancer therapy, their impact on neurodegenerative disorders, and their involvement in protein complexes and enzymatic activity.
最新文献
Translationally controlled tumor protein GmTCTP2 positively regulates plant drought tolerance through GmSCEc mediated SUMOylation

article Full Text OpenAlex

In silico exploration natural compounds for the discovery of novel dnmt3a inhibitors as potential therapeutic agents for acute myeloid leukaemia

article Full Text OpenAlex

Novel Role of Tyrosine Kinase Inhibitors in Managing Chronic Cancer Pain

article Full Text OpenAlex

Development of Hydrazide-Based HDAC6 Selective Inhibitors for Treating NLRP3 Inflammasome-Related Diseases

article Full Text OpenAlex

Therapeutic potential of allosteric HECT E3 ligase inhibition

article Full Text OpenAlex

Sp4/HD11 and Sp1/HAT-p300 complexes induce apoptotic cell death in CuCl2-treated neurons by modulating histone acetylation on BCL-W and BAX promoters.

article Full Text OpenAlex

Visualization analysis of breast cancer-related ubiquitination modifications over the past two decades

article Full Text OpenAlex

Oxidative Stress and Redox Imbalance: Common Mechanisms in Cancer Stem Cells and Neurodegenerative Diseases

review Full Text OpenAlex

A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies

article Full Text OpenAlex

Discovery of 1-phenyl-1,2,3-triazole ureas as dual VEGFR-2/JNK-1 type II kinase inhibitors targeting pancreatic cancer

article Full Text OpenAlex

近5年高被引文献
Modulation of cellular processes by histone and non-histone protein acetylation

review Full Text OpenAlex 523 FWCI20.388

Natural Products in Cancer Therapy: Past, Present and Future

review Full Text OpenAlex 461 FWCI11.881

Metabolic reprogramming and epigenetic modifications on the path to cancer

review Full Text OpenAlex 438 FWCI10.652

Targeted protein degraders crowd into the clinic

review Full Text OpenAlex 344 FWCI9.569

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases

article Full Text OpenAlex 336 FWCI34.724

Epigenetic mechanisms in breast cancer therapy and resistance

review Full Text OpenAlex 336 FWCI8.749

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

article Full Text OpenAlex 332 FWCI78.326

MYC as a target for cancer treatment

review Full Text OpenAlex 329 FWCI8.311

Advances in acute myeloid leukemia

review Full Text OpenAlex 311 FWCI14.24

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

review Full Text OpenAlex 286 FWCI7.462